http://orcid.org/0000-0002-4998-3656
References
- LA L, Al D, Moores LK, et al. Antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e495S–530S.
- Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood. 2005 Oct;106(8):2710–2715.
- Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. 1995;332(20):1330.
- Greinacher A, Farner B, Kroll H, et al. Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients. Thromb Haemost. 2005 Jul;94(1):132–135.
- Linkins LA, Dans AL, Moores LK, et al. Treatment and prevention of heparin-induced thrombocytopenia: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2012;141:e 495S.
- Bircan HA, Alanoglu EG. Massive pulmonary embolism in a patient with heparin induced thrombocytopenia: successful treatment with dabigatran. Eurasian J Med. 2016;48(1):65–68.
- Kelton JG. Heparin-induced thrombocytopenia: an overview. Blood Rev. 2002 Mar;16(1):77–80.
- Warkentin TE, Sheppard JI, Sigouin CS, et al. Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia. Blood. 2006;108(9):2937–2941.
- Warkentin TE, Roberts RS, Hirsh J, et al. An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch Intern Med. 2003;163:2518–2524.
- Gruel Y, Pouplard C, Nguyen P, et al.; French Heparin-Induced Thrombocytopenia Study Group. Biological and clinical features of low-molecular-weight heparin-induced thrombocytopenia. Br J Haematol. 2003 Jun;121(5):786–792.
- Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med. 1996 Nov;101(5):502–507.
- Raschke RA, Curry SC, Warkentin TE, et al. Improving clinical interpretation of the anti-platelet factor 4/heparin enzyme-linked immunosorbent assay for the diagnosis of heparin-induced thrombocytopenia through the use of receiver operating characteristic analysis, stratum-specific likelihood ratios, and Bayes theorem. Chest J. 2013;144(4):1269–1275.
- Cuker A, Crowther M. Clinical practice guideline on the evaluation and management of adults with suspected heparin-induced thrombocytopenia (HIT). Am Soc Hematol. 2013;1:1–4.
- Swan SK, Hursting MJ. The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy. 2000;20:318.
- Wisler JW, Washam JB, Becker RC. Evaluation of dose requirements for prolonged bivalirudin administration in patients with renal insufficiency and suspected heparin-induced thrombocytopenia. J Thromb Thrombolysis. 2012;33:287.
- Kiser TH, Fish DN. Evaluation of bivalirudin treatment for heparin-induced thrombocytopenia in critically ill patients with hepatic and/or renal dysfunction. Pharmacotherapy. 2006;26:452.
- Kleinschmidt S, Stephan B, Pindur G, et al. Argatroban: pharmacological properties and anesthesiologic aspects. Der Anaesth. 2006;55(4):443–450.